{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-020058","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.496000+00:00","generated_at":"2026-05-17T01:33:20.844004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PURE Bioscience FY2025 net product sales $2.2M, net loss narrows to $2.4M from $3.4M","bullets":["Net product sales $2,198K for FY2025, up 12.4% from $1,955K in FY2024.","Net loss improved to ($2.4M) from ($3.4M); loss per share ($0.02) vs ($0.03).","Net cash used in operations ($2.0M) vs ($2.5M) in prior year.","Expanded distribution with Hydrite Chemical; launched membrane treatment for dairy/beverage.","Excluding share-based compensation, net loss was ($2.3M) vs ($3.1M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-020058","json":"https://secwatch.observer/filing/0001493152-25-020058.json","markdown":"https://secwatch.observer/filing/0001493152-25-020058.md","text":"https://secwatch.observer/filing/0001493152-25-020058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315225020058/0001493152-25-020058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315225020058/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:33:20.844004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}